Epstein-Barr virus quietly persists in nearly all adults, yet for roughly 200,000 people annually it triggers cancers including lymphomas and nasopharyngeal carcinoma. Existing therapies either suppress immunity broadly or work inconsistently, leaving a genuine unmet need. A mechanistic target that could selectively disrupt EBV's hijacking of B cells — without collateral immune damage — would represent a meaningful clinical advance.
Published in PNAS, this research identifies SIRT2, a member of the sirtuin family of NAD-dependent deacylase enzymes, as a critical regulator of the metabolic shift that EBV induces in B lymphocytes. When EBV infects B cells, it drives extensive reprogramming of cellular metabolism — essentially forcing the cells into a high-energy, proliferative state that favors viral latency and oncogenic transformation. The investigators show that pharmacological modulators of SIRT2's deacylase activity can interrupt this reprogramming, blocking the EBV-driven transformation process. Notably, the same modulators also affected B cell responses to mitogenic stimulation, suggesting SIRT2 sits at a broader checkpoint in B cell activation metabolism rather than acting through a strictly virus-specific pathway.
Sirtuins have drawn sustained scientific attention for their roles in aging, metabolism, and cancer biology, but SIRT2 has historically been overshadowed by SIRT1 and SIRT3 in immunological contexts. This finding repositions SIRT2 as a potentially druggable node in virus-associated lymphomagenesis. The metabolic reprogramming angle is particularly compelling: rather than targeting viral replication directly — a moving target given EBV's latency programs — this approach disrupts the host cellular machinery the virus depends on. Key limitations to weigh include that the work appears mechanistic and likely preclinical; translation to human therapeutic contexts will require demonstrating selectivity for transformed versus healthy immune cells. Still, for a virus responsible for a substantial global cancer burden with no approved antiviral, this qualifies as a genuinely significant mechanistic advance.